Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH
Recruiting
Early Phase 1
Interventional Study
Neonatal Hyperbilirubinemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 4 Hours – 28 Days
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 250 (estimated)
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if modified diagnosis and treatment (MDT) of neonatal hemolysis (a common cause to newborn jaundice) incorporated with ETCOc measurement (a non-invasive measurement of exhaled gas) works to prevent brain damage in newborns with severe hyperbilirubinemia (sNH). It will also learn about the. occurrence of cranial MRI in the study participants. The main que…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria:
Infants with gestational age of 35(+0) to 41(+6) weeks and birth weight ≥ 2500 grams
* Infants with severe neonatal hyperbilirubinemia, including those whose serum total
* bilirubin (TSB) levels reach above 20 mg/dL or whose TSB levels at any time reach with…
Contacts